Morningstar

Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference

Provided by GlobeNewswire

WAYNE, Pa., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Monday November 16 at 10:30 AM GMT (5:30 AM ET), Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Jefferies Global Healthcare Conference in London, UK.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com


The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

4 Growth Stocks to Buy While They’re Still Undervalued

Plus, the outlook for the AI trade after last week’s selloff.
David Sekera, CFA and Sarah Hansen

3 of the Best Core Stocks to Own

These core stocks with wide economic moats are good long-term investments if you can buy them at a discount.
Susan Dziubinski

3 Great New ETFs From 2026

These ETFs stand out from the rest.
Brendan McCann, CFA

Retirees: 5 Reasons to Consider Index Funds and ETFs

Low fees are just the start. These funds can also make it easier to draw cash for living expenses and manage your portfolio.
Christine Benz

This Newly Undervalued Stock Has Plenty of Growth Ahead

After the recent selloff, this 4-star stock looks more attractive as demand grows for the materials used to make advanced chips.
Seth Goldstein, CFA

Sponsor Center

Site Index
United States Flag United States

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.